Home > Insider Trading > Filing (0001144204-11-044421)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1077183	Neogenomics Inc	NGNM.OB	Services-Testing Laboratories (8734)	742897368

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1518733	M Douglas Oort Van	C/O Neogenomics, Inc. 12701 Commonwealth Drive Suite 9 Fort Myers FL US 33913	Chairman And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2011-08-05	1,956	$1.30	797,456	No	4	P	Indirect	Trust by Self
Common Stock	Acquisiton	2011-08-05	500	$1.25	795,500	No	4	P	Indirect	Trust by Self

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Trust by Self
No	4	P	Indirect	Trust by Self

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	8,600	Direct

Reported Derivative Holdings

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Option (Right to Buy)	$0.80	2009-12-31	2006-03-15	0	1,000,000	Direct
Common Stock	Warrants (Right to Buy)	$1.05	2009-03-16	2014-03-15	0	625,000	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2006-03-15	0	1,000,000	Direct
2014-03-15	0	625,000	Direct

Footnotes

On March 15, 2009 Mr. VanOort was granted options to purchase 1,000,000 shares. The grant was comprised of 500,000 time based options and 500,000 performance based options. The first date of vesting when an option became exercisable was December 31, 2009 when 200,000 performance based options vested. Mr. VanOort will have 374,000 time based options vested and exercisable within 60 days of this filing. There are 300,000 performance based options which are not vested or exercisable.
On March 16, 2009 Mr. VanOort was granted a warrant to purchase 625,000 shares. Of this total 125,000 warrants were immediately exercisable and vested. The remaining 500,000 warrants vest based on performance of the Company stock price and are not exercisable or vested at the present time.